Journal of Autoimmunity

Papers
(The H4-Index of Journal of Autoimmunity is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak3272
The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China609
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?536
The etiology of rheumatoid arthritis347
The 2022 outbreak and the pathobiology of the monkeypox virus260
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19226
Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19212
Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses200
Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies165
Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience159
An overview of autoantibodies in rheumatoid arthritis158
Complement activation and endothelial perturbation parallel COVID-19 severity and activity118
Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection117
The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis112
Systemic autoinflammatory diseases104
Inflammatory markers in systemic lupus erythematosus99
Treg cells in health and autoimmune diseases: New insights from single cell analysis98
Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy94
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy94
COVID-19 convalescent plasma composition and immunological effects in severe patients90
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-1990
The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus85
Ferritin – from iron, through inflammation and autoimmunity, to COVID-1984
Autoimmune hepatitis triggered by SARS-CoV-2 vaccination84
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups83
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients83
The immunobiology of mTOR in autoimmunity77
Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity?73
Auto-immune hepatitis following COVID vaccination71
Sjögren's syndrome: Old and new therapeutic targets71
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients68
Autoimmune hepatitis after COVID-19 vaccine – more than a coincidence66
The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature66
A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination62
Clinical significance of miRNAs in autoimmunity60
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab53
Precision medicine and management of rheumatoid arthritis53
Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up?52
Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-1952
Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data51
Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial50
The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review50
Marginal zone B cells: From housekeeping function to autoimmunity?49
The progress and prospect of regulatory T cells in autoimmune diseases48
Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors46
Innate immunity as the trigger of systemic autoimmune diseases46
JAK/STAT signaling controls the fate of CD8+CD103+ tissue-resident memory T cell in lupus nephritis46
0.027776002883911